Atzeni Fabiola, Muto Pietro, Rodríguez-Carrio Javier, Masala Ignazio Francesco
Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, 98168 Messina, Italy.
Department of Functional Biology, Immunology Area, Faculty of Medicine, University of Oviedo, 33006 Oviedo, Spain.
J Clin Med. 2022 Feb 16;11(4):1029. doi: 10.3390/jcm11041029.
Patients with psoriatic arthritis (PsA) or rheumatoid arthritis (RA) commonly develop renal dysfunction due to either systemic inflammation or drug-related nephrotoxicity. This study compared renal function parameters in patients with PsA versus those with RA and examined the impact of clinical remission or disease relapse on renal function.
This single-center retrospective study was conducted at the University Hospital of Messina, Italy. Adult patients (aged ≥18 years) with PsA or RA who attended the rheumatology clinic within the past 6 months were identified from electronic medical records.
In total, 45 patients with PsA ( = 23) or RA ( = 22) were included. The mean (standard deviation) age was 55.6 (15.9) years, and 78% of participants were female. Patient age, renal function, and medical history were generally similar between the two disease groups, although significantly more RA patients were smokers, and more PsA patients had comorbid hypertension. The prevalence of estimated glomerular filtration rate [eGFR] ≤90 mL/min/1.73 m at 1, 6, and 12 months of treatment ranged from 38.5% to 58.3% in the PsA group and from 45.5% to 54.5% in the RA group and did not significantly differ between disease groups. Clinical remission did not appear to affect renal function parameters in either disease group; however, relapse was associated with significantly higher serum creatinine levels in PsA patients at the same timepoint.
In this study, patients with PsA and RA had a similar prevalence of renal function parameter abnormalities over 12 months of treatment. Disease relapse may impact renal function in patients with PsA.
银屑病关节炎(PsA)或类风湿关节炎(RA)患者常因全身炎症或药物相关肾毒性而出现肾功能障碍。本研究比较了PsA患者与RA患者的肾功能参数,并探讨了临床缓解或疾病复发对肾功能的影响。
本单中心回顾性研究在意大利墨西拿大学医院进行。从电子病历中识别出过去6个月内在风湿科就诊的成年患者(年龄≥18岁),他们患有PsA或RA。
共纳入45例PsA患者(n = 23)或RA患者(n = 22)。平均(标准差)年龄为55.6(15.9)岁,78%的参与者为女性。两组疾病患者的年龄、肾功能和病史总体相似,尽管RA患者吸烟者明显更多,PsA患者合并高血压者更多。在治疗1、6和12个月时,PsA组估计肾小球滤过率[eGFR]≤90 mL/min/1.73 m²的患病率为38.5%至58.3%,RA组为45.5%至54.5%,两组疾病之间无显著差异。临床缓解似乎对两组疾病的肾功能参数均无影响;然而,在同一时间点,疾病复发与PsA患者血清肌酐水平显著升高相关。
在本研究中,PsA和RA患者在12个月的治疗期间肾功能参数异常的患病率相似。疾病复发可能会影响PsA患者的肾功能。